0001217234-25-000046
SEC filingTesting services revenue declined 13% YoY due to prior period adjustments, but volume grew 13%; net loss widened to $8.6M.
For the three months ended June 30, 2025, total revenue decreased 6% to $86.7M from $92.3M in the prior year period. The decline was primarily driven by a 13% drop in testing services revenue to $62.0M, which included a negative $3.8M adjustment for tests performed in prior periods. Excluding this adjustment, testing services revenue would have increased 14% YoY, reflecting volume growth of 13% to 49,500 tests. Product revenue rose 12% to $11.8M, and patient and digital solutions revenue increased 19% to $12.8M.
Gross profit is not separately disclosed, but combined cost of revenues increased slightly. Operating expenses decreased 2% to $97.8M, driven by lower R&D and G&A, partially offset by higher sales and marketing costs. Loss from operations widened 52% to $11.1M, and net loss increased 85% to $8.6M, largely due to the revenue decline and increased sales investments.
Testing services, representing 72% of total revenue, faced headwinds from prior period revenue adjustments but showed strong underlying volume momentum. Management attributed the revenue decline to higher collections in the prior year under ASC 606 and lower collections in the current period for earlier tests. Product revenue growth of 12% was fueled by commercial NGS-based kitted solutions. Patient and digital solutions grew 19%, driven by Ottr software and pharmacy sales. Both product and digital segments are gaining revenue share, partially offsetting testing services weakness.
Management highlighted a cash position of $186M with no debt, supported by a $50M share repurchase during the quarter. A new $50M repurchase program was authorized in May 2025. The company believes existing cash and expected cash flows are sufficient for the next 12 months. No formal revenue or earnings guidance was provided, but the underlying testing services volume growth of 13% and the 14% adjusted revenue increase suggest positive momentum. R&D spending decreased 15% as clinical trial expenses were reduced, while sales and marketing increased 16% to support commercial expansion. Litigation settlement expenses of $0.4M in Q2 and $5.7M year-to-date for the securities class action represent non-recurring charges.
As of June 30, 2025, CareDx holds a strong liquidity position with $68.2M in cash and cash equivalents and $118.0M in short-term marketable securities, totaling $186.2M. The company has no debt, and shareholders' equity stands at $327.4M, down from $378.4M at year-end 2024 due to a net loss and share repurchases. Inventory increased to $27.9M from $19.5M, reflecting higher finished goods and raw materials. Deferred revenue (current) is $6.0M, slightly up from $4.8M.
Operating lease commitments total $33.6M, with maturities extending through 2033. The weighted-average remaining lease term is 4.47 years, and the discount rate is 7.0%. Lease payments are scheduled as: $4.0M in remainder of 2025, $7.9M in 2026, $8.2M in 2027, $7.5M in 2028, $2.6M in 2029, and $3.5M thereafter. Additionally, royalty commitments exist under agreements with Illumina and a university, but no specific dollar amounts are disclosed.
CareDx actively repurchased shares: the February 2025 Repurchase Program of $50.0M was fully utilized, buying back 3.0M shares. A new May 2025 Repurchase Program authorizes another $50.0M, with the full amount available as of June 30. No dividends were paid, and no debt was issued or repaid. Capital expenditures are not detailed in the notes but appear in the cash flow statement at $2.6M for H1 2025.
The company operates as a single reportable segment: transplant diagnostics. Revenue for H1 2025 was $171.4M, up 4.3% from $164.3M in H1 2024. The revenue breakdown by type: Testing Services $124.0M, Product $22.6M, Patient and Digital Solutions $24.8M. Geographically, the U.S. dominates with $161.5M (94.2%), while Rest of World contributed $9.9M. The CODM uses net loss as the primary performance measure, with significant expense categories including personnel ($60.1M), stock-based compensation ($18.4M), and professional fees ($22.5M).